Faculty profile

Lawrence Panasci

ResearcherOncologyMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.

Lawrence Panasci

Researcher

Oncology

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
7 publications in the last five years, latest in 2025.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2012.
Supervised 1 trainee who won CIHR awards, most recently in 2008.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Anti-Apoptotic Protein Bcl-2 Antisense Oligonucleotides Chronic Lymphocytic Leukemia Dna Cages And Nanotubes Drug Resistant Tumors Enzyme-Mediated Repair Of Dna Damage Nucleic Acid Delivery Oligonucleotide Analogues

Latest papers

High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.
Clinical breast cancer · 2025
Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.
Current oncology (Toronto, Ont.) · 2024

All 30 publications

Latest funding

DNA cages as a platform for efficient and selective delivery of therapeutics into tumor cells
NSERC · 2013 · Co-investigator
$200,000
DNA Cages as a Platform for Efficient and Selective Delivery of Therapeutics into Tumor Cells
CIHR · 2012 · Principal investigator
$400,000
c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL)
CIHR · 2010 · Nominated PI
$280,572

All 5 grants and awards

30 publications.

High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.

Labidi S, Mulla N, Elkholi IE, Capella MP, Rose AAN, Panasci L, Ferrario C, Basik M, Fallah P

Clinical breast cancer2025

DOI: 10.1016/j.clbc.2025.04.001 PMID: 40319004

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

Robertson JFR, Shao Z, Noguchi S, Bondarenko I, Panasci L, Singh S, Subramaniam S, Ellis MJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025

DOI: 10.1200/jco.24.00994 PMID: 39772884

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Lazaratos AM, Dankner M, Hamouda A, Labidi S, Cohen V, Panasci L, Friedmann JE, Patenaude F, Ferrario C, Basik M, Rose AAN, Fallah P

Current oncology (Toronto, Ont.)2024

DOI: 10.3390/curroncol32010001 PMID: 39851917

Placental metastasis from maternal NUT carcinoma: diagnostic pitfalls and challenges.

Lai JK, Panasci L, Patey NG, Wang H

BMJ case reports2024

DOI: 10.1136/bcr-2023-259538 PMID: 38569728

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

Lazaratos AM, Maritan SM, Quaiattini A, Darlix A, Ratosa I, Ferraro E, Griguolo G, Guarneri V, Pellerino A, Hofer S, Jacot W, Stemmler HJ, van den Broek MPH, Dobnikar N, Panet F, Lahijanian Z, Morikawa A, Seidman AD, Soffietti R, Panasci L, Petrecca K, Rose AAN, Bouganim N, Dankner M

Breast (Edinburgh, Scotland)2023

DOI: 10.1016/j.breast.2023.04.008 PMID: 37156650

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin.

Sharif-Askari B, Panasci L, Aloyz R

Frontiers in bioscience (Landmark edition)2023

DOI: 10.31083/j.fbl2803052 PMID: 37005765

The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature.

Panet F, Tétreault-Langlois M, Morin V, Sultanem K, Melnychuk D, Panasci L

Cancer reports (Hoboken, N.J.)2022Senior author

DOI: 10.1002/cnr2.1531 PMID: 34409769

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

Assouline S, Amrein L, Aloyz R, Banerji V, Caplan S, Owen C, Hasegawa W, Robinson S, Shivakumar S, Prica A, Peters A, Hagerman L, Rodriguez L, Skamene T, Panasci L, Chen BE, Hay AE

Leukemia & lymphoma2020

DOI: 10.1080/10428194.2020.1734594 PMID: 32154751

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.

Sharif-Askari B, Amrein L, Aloyz R, Panasci L

Breast cancer research and treatment2018Senior author

DOI: 10.1007/s10549-018-4888-6 PMID: 30039287

Precision spherical nucleic acids for delivery of anticancer drugs.

Bousmail D, Amrein L, Fakhoury JJ, Fakih HH, Hsu JCC, Panasci L, Sleiman HF

Chemical science2017

DOI: 10.1039/c7sc01619k PMID: 28989655

Something wrong or missing on this profile? Suggest a correction

Lawrence Panasci

Research

Latest papers

Latest funding

High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Placental metastasis from maternal NUT carcinoma: diagnostic pitfalls and challenges.

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin.

The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature.

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.

Precision spherical nucleic acids for delivery of anticancer drugs.

DNA cages as a platform for efficient and selective delivery of therapeutics into tumor cells

DNA Cages as a Platform for Efficient and Selective Delivery of Therapeutics into Tumor Cells

c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL)

The CIHR/FRSQ Training Program in Cancer Research at McGill

Synergistic effect of DNA-PK inhibitors in the treatment of colon cancer

Frequent collaborators

Mark Basik

Gerald Batist

Gerald Batist

Michael Pollak

Kevin Petrecca

Kevin Petrecca

Sudeep Shivakumar

James Johnston

Christina Wolfson

Nathalie Johnson

Versha Banerji

Bertrand Jean-Claude

Michael Witcher

Howard Bergman

Christina Wolfson

Lawrence Panasci

Research

Latest papers

Latest funding

High Ki-67 expression is associated with increased risk of distant recurrence in Oncotype Dx low risk breast cancer.

Fulvestrant Versus Anastrozole in Endocrine Therapy-Na&#xef;ve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.

Placental metastasis from maternal NUT carcinoma: diagnostic pitfalls and challenges.

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin.

The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature.

IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.

Precision spherical nucleic acids for delivery of anticancer drugs.

DNA cages as a platform for efficient and selective delivery of therapeutics into tumor cells

DNA Cages as a Platform for Efficient and Selective Delivery of Therapeutics into Tumor Cells

c-Abl-directed molecular re-engineering of chlorambucil to offer new therapeutic options to patients with chronic lymphocytic leukemia (CLL)

The CIHR/FRSQ Training Program in Cancer Research at McGill

Synergistic effect of DNA-PK inhibitors in the treatment of colon cancer

Frequent collaborators

Mark Basik

Gerald Batist

Gerald Batist

Michael Pollak

Kevin Petrecca

Kevin Petrecca

Sudeep Shivakumar

James Johnston

Christina Wolfson

Nathalie Johnson

Versha Banerji

Bertrand Jean-Claude

Michael Witcher

Howard Bergman

Christina Wolfson

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.